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Introduction
Depression is commonly associated with poor quality of sleep and forms an essential criterion for the diagnosis of the condition. Studies have also suggested that up to 90% of patients suffering from major depressive disorders experience some type of sleep disruption 1, 2 . Persistent sleep disturbances are also a risk factor to depression 3 . Disturbance of sleep is a common problem in depressed patients and antidepressant drugs frequently been prescribed to manage sleep related problem in such patient 4 . Sleep deprivation aggravates health risk factors including depression, anxiety 5, 6 , cognitive dysfunctions 7, 8, 9 , impaired motor activity 10 , behavioral irritability and poor performance. Sleep deprivation weaken anti-oxidative 11, 13 defense capacity. It also impairs antioxidant defense, leading to oxidative damage by causing imbalance between oxidants and antioxidants 13 .
Lower doses of antidepressants are frequently prescribed to manage insomniac patients without depression 14 . Tricyclic antidepressants (TCAs) have been reported to improve sleep continuity in such patients 15 whereas most selective serotonin reuptake inhibitors (SSRIs) may exhibit alerting effects, thereby reducing TST and sleep efficiency, and increasing wakefulness 15, 16 .
Trazodone is a second-generation antidepressant which blocks 5-HT 2 receptors.
However, its scientific and mechanistic basis of antidepressants use in the treatment and management of sleep deprivation is not understood properly so far. Further, no adequate information available to understand the mechanism of their clinical potential in sleep deprivation. However, complex interactions of oxidative stress and nitric oxide have been suggested in sleep regulation. Within the later dorsal tegmentum (LDT), pedunculopontine tegmentum and dorsal rephe nucleus, nitric oside (NO)containing neurons overlap and grouped according to their contribution to sleep mechanisms 17 . The main target for NO is the soluble gunaylate cyclase that triggers overproduction of cyclic guanosine monophoshate. In neurons of the pontine tegmentum, NO facilitates sleep and has been implicated in several oxidative neurodegenerative disorders 18, 19 .
Despite extensive research on the beneficial effects of trazodone and NO modulators in various disease conditions, limited studies explored the possible therapeutic potential of antidepressant in the treatment of sleep deprived-induced behavioral alterations and oxidative stress. Therefore, the present study has been designed to investigate the possible nitric oxide modulation in the protective effects of trazodone against sleepdeprivation-induced anxiety like behavior and oxidative stress.
Materials and Methods

Animals
Albino mice weighing 22 -30 g, bred in Central Animal House (CAH) facility of the Panjab University, Chandigarh, India were used for this study. The animals were housed under standard laboratory conditions, maintained on natural light and dark cycle and had free access to food and water. They were acclimatized to laboratory conditions before the experiment. The animals were divided into 10 groups consists of 6 animals in each group. All experiments were carried out in daylight. The experimental protocol was approved by Institutional Animal Ethics Committee (IAEC) and conducted according to the Indian National Science Academy Guidelines for the use and care of experimental animals.
Drugs and treatment schedule
Animals were divided into different groups. Naïve (saline) and control (sleep deprived) were treated as groups 1 and 2. Animals that received trazodone (5 mg/kg, 10 mg/kg), Larginine (50 mg/kg, i.p), L-NAME (10 mg/kg, i.p) and methylene blue (10 mg/kg, i.p) were Int J Health Res, September 2008; 1(3): 153 treated as groups 3 to 7, respectively, while those that received L-arginine (50 mg/kg, i.p), L-NAME (10 mg/kg, i.p) and methylene blue (10 mg/kg, i.p) after 10 min pretreatment with trazodone (5 mg/kg) were treated as group 8 to 10, respectively. Trazodone, L-arginine, L-NAME and methylene blue were freshly prepared in distilled water and administered intraperitoneally for 5 days, 2 days prior to 72 hr sleep deprivation.
Sleep deprivation
The animals were sleep deprived for 72 hr by placing them on grid suspended over water, based on modified method of Sinomiya et al 20 . Briefly, they were placed on a grid floor (29×15×7 cm) inside the plastic cage filled with water to 1 cm below the grid surface for 72 hr. The stainless steel rods of the grid (3 mm wide) were set 2 cm apart from each other. Food and water were provided ad libitum.
Behavioral assessments
Anxiety levels were measured using the following approaches: Zero maze test-The Zero maze described by Shepard 22 is a modification of elevated plus maze model of anxiety in rodents. The maze comprised of black perspex annular platform (105 cm diameter, 10 cm width) elevated to 65 cm above ground level, divided equally into four quadrants. Black Perspex walls (27 cm height) on both the inner and outer edges of the platform enclosed two opposite quadrants; the remaining two quadrants were surrounded by Perspex lip (1 cm in height). An animal was placed in the closed quadrant. During the 5 min test, the average time spent per entry in open quadrant of the maze was recorded.
Mirror Chamber Test-Animals were placed individually at the distal corner of a mirror chamber at the beginning of the test. The mirror chamber consisted of a wooden chamber having a mirror chamber enclosed within it. During the 5 min test session, the latency to enter the mirror chamber and average time spent per number of entries in mirror chamber were recorded. An anxiogenic response was defined as the reduced number of entries and time spent in the mirror chamber 23 .
Measurement
of locomotor activity-Ambulatory movements were recorded by using actophotometer (IMCORP, India). The apparatus was placed in a darkened, lightsound attenuated and ventilated testing room. Before locomotor task, animals were placed individually in the activity meter for 3 min. The ambulatory movements were recorded using actophotometer for a period of 5 min and expressed in terms of total photo beam counts for 5 min per animal 24 .
Biochemical tests
Tissue preparation
Animals were sacrificed by decapitation on the same day following behavioral assessments. The brains were removed, rinsed in isotonic saline and weighed. A 10% (w/v) tissue homogenate was prepared with 0.1M phosphate buffer (pH 7. 
Lipid peroxidation assay
The quantitative measurement of lipid peroxidation in the whole brain was measured according to the method of Wills 25 . The amount of malondialdehyde formed was measured by the reaction with thiobarbituric acid at 532 nm using Perkin Elmer lambda 20
spectrophotometer. Results were expressed as moles of malondialdehyde per milligram protein.
Estimation of reduced glutathione
Reduced glutathione in the brain was estimated according to the method of Ellman 26 . A 1.0 ml of homogenate was precipitated with 1.0 ml of 4% sulfosalicylic acid by keeping the mixture at 4 °C for 1 hr and the samples were immediately centrifuged at 1200 ×g for 15 min at 4 °C. The assay mixture contains 0.1 ml of supernatant, 2.7 ml of phosphate buffer of pH 8.0 and 0.2 ml of 0.01 M dithiobisnitrobenzoic acid (DTNB). The yellow color developed was read immediately at 412 nm using Perkin Elmer Lambda 20 spectrophotometer. Results were expressed as micromole GSH per milligram protein.
Nitrite estimation
Accumulation of nitrite was measured in cell free supernatants from brain homogenates by spectrophotometer assay based on Greiss reagent 15 (1% sulphanilamide 0.1% naphthylethylenediamine dihydrochloride 2.5% phosphoric acid) incubated at room temperature for 10 min to yield a chromophore. Nitrite is the stable product of nitric oxide (NO) in living system. Absorbance was read at 543 nm spectrophotometrically.
The nitrite concentration was calculated from a standard curve using sodium nitrite as standard and expressed as micro molar nitrite per milliliter homogenate 27 .
Protein estimation
The protein content was measured according to the method of Lowry 28 using bovine serum albumin as standard.
Catalase estimation
Catalase activity was assayed by the method of Luck 1971 29 , wherein the breakdown of hydrogen peroxides (H 2 O 2 ) was measured at 240 nm. Briefly, assay mixture consisted of 3 ml of H 2 O 2 phosphate buffer and 0.05 ml of supernatant of tissue homogenate (10%). The change in absorbance was recorded at 240 nm and the results were expressed as micromole H 2 O 2 decomposed per milligram of protein/min.
Statistical analysis
All the values are expressed as mean ± SEM. The data were analyzed using analysis of variance (ANOVA) followed by Tukey test. At 95% confidence interval, p values less than 0.05 were considered to be significant.
Results
Effects of trazodone and its modulation by L-NAME, L-arginine and methylene blue on anxiety like behavior of sleepdeprived mice
Plus maze and Zero maze
Sleep deprivation for 72 hr significantly decreased average time spent per entry in open arm of plus maze performance task and zero maze as compared to naïve group (without sleep deprivation). Treatment with trazodone (5 and 10 mg/kg, ip) significantly increased the average time spent per entry in open arm in plus maze performance task and zero maze as compared to control (sleep deprived) (p<0.05) as shown in Table  1 . L-NAME (selective nitric oxide synthase inhibitors, 10 mg/kg, per se), methylene blue (non selective nitric oxide synthase inhibitors, 10 mg/kg, per se), pretreatment of the animals produced anti-anxiety like behavior in both the test models (Table 1) . However, L-NAME (5 mg/kg), and methylene blue (10 mg/kg), pretreatments with trazodone (5 mg/kg) caused potentiation of antianxiety like effect as compared to their effect per se (p<0.05). There was increased average time spent per entry in open arm in both the test paradigm tasks. However, L-NAME (5 mg/kg) and methylene blue (10 mg/kg) per se did not produce any significant effect as compared to control (p<0.05). Further, L-arginine (nitric oxide precursor, 50 mg/kg) pretreatment with trazodone (5 mg/kg) reversed the protective effect of trazodone and reduced average time spent per entry in open arm as compared to trazodone (5 mg/kg) in both the test tasks (p<0.05). L-arginine (50 mg/kg) per se did not show any significant effect on anxiety like behavior in both the test models as compared to control (p<0.05).
Mirror chamber
The sleep deprivation significantly delayed the latency to enter in mirror chamber, decreased average time spent per entry in the mirror chamber as compared to the naïve group (without sleep deprivation). Treatment with trazodone (5 and 10 mg/kg, ip) for 5 days significantly shortened the latency to enter mirror chamber and increased average time spent per entry in mirror chamber as compared to control (sleep deprived) (p<0.05) as shown in Table 2 . L-NAME (5 mg/kg) and methylene blue (10 mg/kg) pretreatment with trazodone (5 mg/kg) caused further improvement in their antianxiety effect (decreased latency to enter mirror chamber and increased average time spent per entry in mirror chamber) which was significant as compared to their effect per se (p<0.05). L-NAME (10 mg/kg, per se) and methylene blue (10 mg/kg, per se) did not produce any significant effect on anxiety like behavior as compared to control (p<0.05). Further, pretreatment with L-arginine (50 mg/kg) with trazodone (5 mg/kg) reversed the antianxiety-like effect of trazodone. There was delayed latency to enter mirror chamber and reduced average time spent per entry in mirror chamber as compared to trazodone (5 mg/kg) (p<0.05). L-arginine (50 mg/kg per se) did not produce any significant effect on anxiety-like behavior as compared to control (p<0.05).
Effects of trazodone and its modulation by L-NAME, L-Arginine and methylene blue on locomotor activity of sleepdeprived mice
The effects of trazodone and its modulation by L-NAME, L-Arginine and methylene blue on locomotor activity of sleep-deprived mice are given in Table 3 . The locomotor activity of the 72 hr sleep deprived mice were significantly reduced as compared to naïve mice. Treatment with trazodone (5 and 10 mg/kg, ip) for 5 days significantly improved locomotor activity (p<0.05). L-NAME (10 mg/kg) per se and methylene blue (10 mg/kg) per se and its pretreatment with trazodone (5 mg/kg) did not significantly influence the locomotor activity as compared to their own effect alone (p<0.05). Similarly, L-arginine (50 mg/kg) per se and its combination with trazodone (5 mg/kg) did not influence locomotor activity as compared to their own effect alone.
Effects of trazodone and its modulation by L-NAME, L-arginine and methylene blue on oxidative stress parameters of sleep-deprived brain
The effects of trazodone and its modulation by L-NAME, L-arginine and methylene blue on oxidative stress parameters of sleepdeprived brain are shown in Table 4 . The 72 hr sleep deprivation significantly increased lipid peroxidation, nitrite levels, depleted reduced glutathione level and catalase activity in the mice (p<0.05). Treatment with trazodone (5 and 10 mg/kg, ip) significantly restored reduced glutathione and catalase activity, attenuated elevated lipid peroxidation and nitrite concentration as compared to 72 hr sleep deprived mice (p<0.05). L-NAME (10 mg/kg) and methylene blue (10 mg/kg) pretreatment with trazodone (5 mg/kg) caused further significant potentiation in their antioxidant activity as compared to their effect per se (p<0.05). However, L-NAME (10 mg/kg) per se and methylene blue (10 mg/kg) per se treatment did not have any significant effect on the antioxidant level as compared to the control (P<005). Further, L-arginine (50 mg/kg) pretreatment with trazodone (5 mg/kg) significantly reversed the protective effect of trazodone (5 mg/kg) (p<0.05).
Discussion
Disturbance in sleep is a common problem 30 that requires appropriate diagnosis and management, whether it is due to anxiety, depression or a hectic lifestyle. A number of neuropsychiatric problems such as depression, anxiety, psychosis occur due to chronic sleep deprivation that impairs brain functions and contributes to allostatic load of the body. Several research reports suggest that sleep has an important role in motor activity, anxiety level, memory dysfunction, body weights and metabolic function, such as reduced anabolic hormones, etc 31, 32 . However, the mechanism of these behavioral Table 3 : Effects of trazodone and its modulation by L-NAME, L-arginine and methylene blue on locomotor activity of sleep-deprived mice In the present study, 72 hr sleep deprivation caused significant impairment in locomotor activity and anxiety-like behavior in animals.
Silva et al 33 have also reported that sleep deprivation causes anxiety-like behavior and influence motor behavior. Increased cortisol level has been linked with anxiety-like behavior and decreased motor behavior response in humans 34 . Sleep deprivation significantly influence brain functions and causes long-term changes in multiple neural systems. Marked behavioral changes might be due to alterations in the brain regions controlling motor activity and anxiety like behavior 33, 35, 36 .
Trazodone is a well-known antidepressant drug used in the management of mild to moderate depression. Antidepressant drug treatment has also been reported to improve quality of sleep 37 , sleep efficiency 37 . Besides, antidepressant drug treatment also improves motor activity 38 , antianxiety 31, 38 , and antioxidative effect 39, 40 .
In our study, trazodone treatment significantly improved locomotor activity and produced antianxiety effect in all the behavior paradigms suggesting therapeutic potential of the drug in the management of behavioral alterations associated with sleep deprivation.
Recently, the role of oxidative stress has been suggested in sleep deprivation 41 . Reports suggest that sleep deprivation increase free radicals and weakens oxidative defense by altering the balance between oxidants and antioxidant defense 11, 42, 43 . Oxidative stress indicators (lipid peroxidation, nitrite level) and antioxidant defense parameters (glutathione, catalase level) may be useful to understand the oxidative damage cascades in sleep deprivation. However, little is known as to whether stress is an important consequence of sleep deprivation. In our study, 72-hr sleep deprivation caused significantly oxidative damage as indicated by raised lipid perooxidation, nitrite concentration. Free radicals are well known to initiate a cellular cascade, causing lipid peroxidation, DNA damage and cell death. Besides, 72 hr sleep deprivation also weakened the antioxidant defense as evidenced by depletion of reduced glutathione and catalase activity. This suggests that the sleep deprivation cause significant oxidative damage possibly by unbalancing oxidative and antioxidant defense mechanism. The brain is more sensitive to oxidative damage due to an abundant presence of polyunsaturated fatty acids, a deficient antioxidant defense and high rate of oxygen utilization due to higher metabolic rate 12, 34 . Ramanthan et al 11 also reported a significant decrease in superoxide dismutase activity in hippocampus and brain stem of sleepdeprived rat.
Nitric oxide (NO), an intercellular messenger in the brain, plays a crucial role in various physiological and pathological processes 44, 45 . It also modulates sleep-wake rhythm of living beings. However, its exact role in sleep deprivation is still not clear 46, 47 . Any pharmacological manipulation of nitric oxide pathway may be considered as a novel therapeutic approach for the management of sleep and related stress disorder. NO is an important neuromodualtor which plays a key role in sleep homeostasis from the fact that administration of a NOS inhibitor suppresses sleep rebound occurring in response sleep deprivation 48 . In our study, pretreatment with L-arginine (nitric oxide precursor) with trazodone, caused reversal of anti-anxiety like behavior and antioxidant effect of trazodone suggesting the involvement of free radical that influence sleep deprivationinduced behavioral and biochemical alterations. Beside, it has been reported that nitric oxide is involved in the mechanism of anxiety 49, 50 . Antidepressant drugs also acts by involving NO-cGMP pathway 51 .
L-Arginine (NO precursor) caused anxiety like behavior in all the tests paradigm tasks in our study, indicating that NO may be an anxiogenic substance. However, its exact role in the neurobiology of anxiety is still unclear. NO reacts with reactive oxygen species and act as an oxidant agent. The oxidation is not specific and affects any cell molecule. Besides, NO reacts with reactive oxygen species quickly enough to avoid the action of antioxidant system, forming peroxynitrite anion (ONOO -) 44, 45 . However, the role of reactive oxygen species -reactive nitrogen species (ROS-RNS) and its interaction with NO in the regulation of stress Int J Health Res, September 2008; 1(3): 160 responses are, so far, not clearly understood. Further, reports indicate that systemic administration of L-NAME (selective NOS inhibitor) and methylene blue (non-selective NOS inhibitor) cause's anxiolytic and antioxidant effect 49, 52 . Further, co-administration of L-NAME and methylene blue pretreatment with trazodone caused the potentiation of trazodone's protective effect against sleep deprivation induced behavioral alteration and oxidative damage, suggesting the involvement of nitric oxide pathway. However, both l-arginine and L-NAME and its pretreatment with trazodone did not produce any significant effect on locomotor activity of the animals, suggesting that nitric oxide is not significantly involved in these effects. Ou study further suggests the possibility that the inhibition of nitric oxide synthase pathway could be used as a strategy to enhance the clinical efficacy of trazodone.
Conclusion
The present study has shown that nitric oxide modulation is involved in the protective effect of trazodone. In addition, the protective effects of trazodone might be partially due to its antioxidant activity.
